PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
暂无分享,去创建一个
J. Carles | J. Bono | Choung-Soo Kim | A. Font | M. Eisenberger | P. Parente | L. Geczi | A. Hardy-Bessard | G. Kacso | M. Chadjaa | L. Mourey | D. Ford | J. Bernard | Wenping Zhang